Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
Industry Leader Brings Decades of Strategic Clinical and Cell Therapy Expertise as Orna Advances New Class of panCAR in vivo CAR RNA Medicines
隨着 Orna 推出新一類 PanCAR 體內 CAR RNA 藥物，行業領導者帶來了數十年的戰略臨床和細胞療法專業知識
WATERTOWN, Mass., April 11, 2024 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNA), today announced that Frank Neumann, M.D., Ph.D., will join the Company as Chief Medical Officer. In addition, Dr. Neumann will join MPM BioImpact, which built and led the launch of Orna, as an Entrepreneur Partner.
馬薩諸塞州沃特敦，2024 年 4 月 11 日 /PRNewswire/ — Orna Therapeutics，一家致力於設計和交付全新一類全新環狀核糖核糖核酸療法 (orNA) 的生物技術公司），今天宣佈，醫學博士、博士弗蘭克·諾伊曼將加入公司，擔任首席醫療官。此外，諾伊曼博士將作爲企業家合作伙伴加入MPM BioImpact，該公司創建並領導了Orna的推出。
"We are delighted to welcome Frank, an accomplished leader with a proven track record in CAR-based cell therapy and clinical development," said Tom Barnes, Ph.D., Chief Executive Officer of Orna Therapeutics. "His deep industry expertise, from proof-of-concept to clinical evaluation and beyond, will serve Orna well as we reshape RNA therapeutics to realize new treatment possibilities in hematological malignancies, autoimmune diseases and beyond."
Orna Therapeutics首席執行官湯姆·巴恩斯博士表示：“我們很高興歡迎弗蘭克，他是一位出色的領導者，在基於CAR的細胞療法和臨床開發方面有着良好的記錄。”“從概念驗證到臨床評估等，他深厚的行業專業知識將爲Orna提供良好的服務，幫助我們重塑RNA療法，爲血液系統惡性腫瘤、自身免疫性疾病等實現新的治療可能性。”
"Orna's truly innovative approach to RNA therapeutics shows incredible promise to fundamentally change the way life-threatening diseases are treated," said Dr. Neumann. "I very much look forward to supporting this work to deliver new medicines for patients."
諾伊曼博士說：“Orna真正創新的RNA療法有望從根本上改變危及生命的疾病的治療方式。”“我非常期待支持這項工作，爲患者提供新藥。”
"Frank is a distinguished expert in advancing cell therapies into the clinic and through regulatory milestones," said Ansbert Gadicke, M.D., Chairman of the Board, Orna, and Managing Partner, MPM BioImpact. "I am confident he will make significant contributions to the advancements and applications of Orna's novel circular RNA technology."
Orna董事會主席兼MPM BioImpact管理合夥人安斯伯特·加迪克醫學博士說：“弗蘭克是推動細胞療法進入臨床和實現監管里程碑方面的傑出專家。”“我相信他將爲Orna的新型環狀RNA技術的進步和應用做出重大貢獻。”
Dr. Neumann will join Orna from Kite, a Gilead Company, where he currently serves as Senior Vice President and Global Head of Clinical Development. He previously held positions as Chief Medical Officer at Verastem, Inc. (also known as Verastem Oncology) and as Vice President, Head of Oncology Clinical Research at bluebird bio. In addition, Dr. Neumann served as clinical development head for all of Takeda Pharmaceuticals cell therapy approaches globally, and held various leadership roles of increasing prominence, including global clinical lead and medical team lead for two distinct cancer therapies. Earlier in his career, he was a member of the oncology medical teams at AstraZeneca and Sanofi-Aventis.
諾伊曼博士將從吉利德旗下的Kite加入Orna，他目前擔任該公司的高級副總裁兼臨床開發全球主管。他之前曾在Verastem, Inc.（也稱爲Verastem Oncology）擔任首席醫學官和藍鳥生物副總裁兼腫瘤學臨床研究主管。此外，諾伊曼博士曾擔任武田製藥全球所有細胞療法的臨床開發主管，並擔任過越來越重要的各種領導職務，包括兩種不同癌症療法的全球臨床負責人和醫療團隊負責人。在他職業生涯的早期，他是阿斯利康和賽諾菲安萬特腫瘤醫療團隊的成員。
In addition to his extensive industry experience, Dr. Neumann is board certified in Hematology/Oncology, Internal Medicine and Palliative Care Medicine. He was a research scholar at the University of Texas MD Anderson Cancer Center and is currently an assistant professor at the Heinrich Heine University in Düsseldorf, Germany. He earned his M.D. from the Heinrich Heine University and his Ph.D. from the Rheinische-Friedrich-Wilhelm University in Bonn, Germany.
除了豐富的行業經驗外，諾伊曼博士還獲得了血液學/腫瘤學、內科和姑息治療醫學的董事會認證。他曾是德克薩斯大學醫學博士安德森癌症中心的研究學者，目前是德國杜塞爾多夫海因裏希·海涅大學的助理教授。他在海因裏希·海涅大學獲得醫學博士學位，在德國波恩的萊茵-弗里德里希-威廉大學獲得博士學位。
About Orna Therapeutics
關於奧納療法
Orna Therapeutics is a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA (oRNA) therapeutics with the potential to change the way we treat disease. Orna's proprietary platform combines novel technology to design circular RNA transcripts that drive protein expression with validated and unique delivery solutions. oRNA has many advantages over traditional mRNA approaches, including simplified production, improved formulatability, and superior protein expression – making it a highly disruptive, new class of RNA therapeutics with vast potential to change patient's lives. To learn more visit: and follow Orna Therapeutics on Twitter and LinkedIn.
Orna Therapeutics 是一家生物技術公司，致力於設計和交付全新一類完全工程化的環狀核糖核酸 (orNA) (orNA)）有可能改變我們治療疾病的方式的療法。Orna 的專有平台結合了新技術，設計了環狀 RNA 轉錄本，通過經過驗證的獨特遞送解決方案推動蛋白質表達。orna 與傳統的mRNA方法相比具有許多優勢，包括簡化生產、提高配方能力和卓越的蛋白質表達，使其成爲一種極具顛覆性的新型RNA療法，具有改變患者生活的巨大潛力。要了解更多信息，請訪問： 然後繼續關注 Orna Therapeutics 推特 和 領英。
SOURCE Orna Therapeutics
來源 Orna Therapeutic
譯文內容由第三人軟體翻譯。